Skip to content
Pharma Observatory a Scientist.com platform

Gene

FOXA1

FOXA1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (24), Actionable biomarkers (1), Target-disease associations (331), and 6 more evidence types, each linked to its source.

Ensembl ENSG00000129514 UniProt P55317 Matched to Ensembl and UniProt
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Assay-provider ledger Assay-provider ledger 24 Actionable biomarkers Actionable biomarkers 1 Target-disease associations Target-disease associations 331 Vendor sourcing Vendor sourcing 2 Trial-cited literature Trial-cited literature 177 Protein variant mentions Protein variant mentions 6 Human sample screening reference Human sample screening reference 2 Literature-extracted relations Literature-extracted relations 17 Assay-provider ledger Assay-provider ledger 24 Actionable biomarkers Actionable biomarkers 1 Target-disease associations Target-disease associations 331 Vendor sourcing Vendor sourcing 2 Trial-cited literature Trial-cited literature 177 Protein variant mentions Protein variant mentions 6 Human sample screening reference Human sample screening reference 2 Literature-extracted relations Literature-extracted relations 17

Rows recorded per section (log scale)

1 more section with rows · 3 sections measured, none recorded

Cancer actionable (CGI)

Curated as clinically actionable in cancer by the Cancer Genome Interpreter.

Get the FOXA1 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Evidence over time

Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention FOXA1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.

Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.

The yearly numbers
FOXA1 per year, by evidence type, the most recent 10 years, newest first; the chart covers 1990 to 2023. The share is of the papers our biomarker dictionary matched that year, not of the literature at large, and a blank year is one our matched corpus does not cover at all.
Year Publication mentions Share of that year
2023 15 of 11,460 0.13%
2022 15 of 13,598 0.11%
2021 23 of 15,045 0.15%
2020 13 of 14,459 0.09%
2019 12 of 12,159 0.10%
2018 17 of 11,854 0.14%
2017 16 of 11,595 0.14%
2016 9 of 10,983 0.08%
2015 16 of 11,395 0.14%
2014 10 of 10,367 0.10%

Showing 10 of 34 years.

Start your 14-day trial Email me all 34 years as a PDF

Assay-provider ledger (24)

Shown in this order: most recent publication first.

Assay-provider ledger
Company Provider class Validation Papers Most recent publication
OmixScience Co., Ltd Diagnostic provider Clinical validationAnalytical validation 1 March 06, 2026
OmixScience Research Institute Diagnostic provider Clinical validationAnalytical validation 1 March 06, 2026
Nanjing Geneseeq Technology Inc Diagnostic provider Clinical validation 1 September 30, 2025
Acornmed Biotechnology Diagnostic provider Clinical validation 1 December 17, 2024
Gibco; Life Technologies; Thermo Fisher Scientific, Inc. Reagent supplier Clinical validationAnalytical validation 1 February 01, 2020

Showing 5 of 24 assay-provider companies.

Start your 14-day trial Email me all 24 assay-provider companies as a PDF

Actionable biomarkers (1)

Shown in this order: fixed catalogue order, not ranked.

Actionable biomarkers
Alteration Drug Response Disease Source
FOXA1 amplification Bcl2 Inhibitors response-associated colorectal adenocarcinoma Cancer Genome Interpreter

Target-disease associations (331)

Shown in this order: fixed catalogue order, not ranked.

Target-disease associations
Disease Therapeutic area Source
3-hydroxy-3-methylglutaryl-CoA synthase deficiency genetic, familial or congenital disease Mouse knockout (IMPC)
Abnormal pupillary function phenotype GWAS credible sets
Abruptio Placentae pregnancy or perinatal disease GWAS credible sets
Acute hepatic failure phenotype Expression Atlas
Adrenocorticotropic hormone deficiency endocrine system disease Mouse knockout (IMPC)

Showing 5 of 331 associations.

Start your 14-day trial Email me the first 50 associations as a PDF

Vendor sourcing (2)

Shown in this order: alphabetical by organization.

Vendor sourcing
Organization Role Tier Evidence Citation
Ambry Genetics (United States) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission The c.466G>A (p.G156S) alteration is located in exon 2 (coding exon 2) of the FOXA1 gene. This alteration results from a G to A substitution at nucleotide po... View ClinVar record SCV003528614.3
Labcorp Holdings Inc. Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission No supporting text recorded; see the citation. View ClinVar record SCV001045870.1

Trial-cited literature (177)

Shown in this order: newest first, then most cited.

Trial-cited literature
Publication Journal Year Citations
The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. Pharmacology research & perspectives 2025 1
5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies. medRxiv : the preprint server for health sciences 2024 2
Biomarkers in Cancer Detection, Diagnosis, and Prognosis. Sensors (Basel, Switzerland) 2023 222
Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. Cells 2023 77
OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer discovery 2023 33

Showing 5 of 177 papers.

Start your 14-day trial Email me the first 50 papers as a PDF

Protein variant mentions (6)

Shown in this order: alphabetical by variant.

Protein variant mentions
Variant Distinct papers Year range Sample papers
p.I10X 1 2019 PMID 31243370
p.L309F 1 2022 PMID 36215125
p.M0543L 1 2019 PMID 31243370
p.M253K 1 2019 PMID 31243370
p.Y259C 1 2019 PMID 31243370

Showing 5 of 6 variants.

Start your 14-day trial Email me all 6 variants as a PDF

Human sample screening reference (2)

Shown in this order: alphabetical by variant.

Human sample screening reference
Variant GDC project Disease / site Affected cases Profiled cases Observed frequency 95% interval
p.M253K TCGA-PRAD Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Acinar Cell Neoplasms; Ductal and Lobular Neoplasms; Prostate gland 1 500 0.20% 0.04% to 1.12%
p.Y259C TCGA-BRCA Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast 1 1,098 0.09% 0.02% to 0.51%

Literature-extracted relations (17)

Shown in this order: chemicals, then diseases.

Literature-extracted relations
Related entity Kind Source relation label Paper Year
Selegiline Chemical negative_correlate The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. 2025
Neoplasms Disease associate The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents. 2025
Prostatic Neoplasms Disease associate 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies. 2024
Colorectal Neoplasms Disease associate A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. 2021
Lymphatic Metastasis Disease associate A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. 2021

Showing 5 of 17 relation assertions.

Start your 14-day trial Email me all 17 relation assertions as a PDF

Organizations publishing (343)

Shown in this order: most papers first.

Organizations publishing
Organization Type Papers Years
Memorial Sloan Kettering Cancer Center Hospital 16 2013 to 2020
Dana-Farber Cancer Institute Other 13 2014 to 2023
Harvard Medical School Academic 11 2013 to 2023
University of North Carolina System Academic 9 2006 to 2017
Mass General Brigham Hospital 8 2008 to 2022

Showing 5 of 343 organizations.

Start your 14-day trial Email me the first 50 organizations as a PDF

Where FOXA1 appears

  • animal disease
  • cancer or benign tumor
  • cardiovascular disease
  • disorder of visual system
  • endocrine system disease
  • gastrointestinal disease
  • genetic, familial or congenital disease
  • hematologic disease
  • immune system disease
  • infectious disease
  • injury, poisoning or other complication
  • integumentary system disease
  • measurement
  • nervous system disease
  • nutritional or metabolic disease
  • phenotype
  • pregnancy or perinatal disease
  • respiratory or thoracic disease
  • urinary system disease

305 diseases touched.

Not on this page

Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and trial mentions.

Browse all biomarker evidence pages